Mycobacterium tuberculosis (Mtb) and Rhodococcus jostii RHA1 have similar cholesterol catabolic pathways. This pathway contributes to the pathogenicity of Mtb. The hsaAB cholesterol catabolic genes have been predicted to encode the oxygenase and reductase, respectively, of a flavin-dependent mono-oxygenase that hydroxylates 3-hydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione (3-HSA) to a catechol. An hsaA deletion mutant of RHA1 did not grow on cholesterol but transformed the latter to 3-HSA and related metabolites in which each of the two keto groups was reduced: 3,9-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-17-one (3,9-DHSA) and 3,17-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-9-one (3,17-DHSA). Purified 3-hydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione 4-hydroxylase (HsaAB) from Mtb had higher specificity for 3-HSA than for 3,17-DHSA (apparent k cat /K m ‫؍‬ 1000 ؎ 100 M ؊1 s ؊1 versus 700 ؎ 100
Mycobacterium tuberculosis (Mtb), 6 the most devastating infectious agent of mortality worldwide (1) , remains a primary public health threat due to synergy with the human immunodeficiency virus and the emergence of extensively drug-resistant strains. Mtb has the unusual ability to survive and replicate in the hostile environment of the macrophage (2, 3) utilizing largely unknown mechanisms. Genes essential to intracellular survival have been identified using genome-wide mutagenesis (4) . A cluster of such genes was subsequently predicted to specify cholesterol catabolism (5) . Targeted gene deletion studies subsequently indicated that cholesterol catabolism occurs throughout infection, contributing to the virulence of Mtb (6 -8) . Although the exact role of cholesterol in infection remains unclear, the gene deletion studies are consistent with the high concentrations of cholesterol found within caseating granulomas and the observed congregation of bacteria around cholesterol foci (9) .
The cholesterol catabolic pathway of Mtb is very similar to that of other pathogenic and environmental actinomycetes (10) , as initially predicted in Rhodococcus jostii RHA1 (5) . Sidechain degradation is initiated by a cytochrome P450 and proceeds via a ␤-oxidative process (11) . Degradation of the fourringed steroid nucleus is initiated by 3␤-hydroxysteroid dehydrogenase (3␤-HSD), yielding 4-cholestene-3-one (12) . The extent to which side-chain and ring degradation occur concurrently is unclear. Ring degradation involves the successive actions of 3-ketosteroid-1⌬-dehydrogenase and 3-ketosteroid 9␣-hydroxylase, which result in the opening of ring B with concomitant aromatization of ring A to yield a phenol, 3-hydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione (3-HSA) (13) (14) (15) (16) (17) . The phenolic ring of the latter has been predicted to be hydroxylated by HsaAB to yield a catechol, 3,4-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione (3,4-DHSA) ( Fig. 1) 1 Both authors contributed equally to this work. 2 Recipient of a postdoctoral fellowship from the Deutsche Forschungsgemeinschaft. 3 Recipients of a postdoctoral fellowship from MSFHR. 4 An HHMI International Scholar and an MSFHR Senior Scholar. 5 To whom correspondence should be addressed: 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada. Tel.: 604-822-0042; Fax: 604-822-6041; E-mail: leltis@interchange.ubc.ca. 6 The abbreviations used are: Mtb, M. tuberculosis; HsaAB, 3-hydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione 4-hydroxylase; 3-HSA, 3-hydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione; 3,17-DHSA, 3,17-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-9-one; 3,9-DHSA, 3,9-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-17-one; 3,9,17-THSA, 3,9,17-trihydroxy-9,10-seconandrost-1,3,5(10)-triene; 3,4-DHSA, 3,4-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione; 3,4,17-THSA, 3,4,17-trihydroxy-9,10-seconandrost-1,3,5(10)-triene-9-one; 3,4,9-THSA, 3,4,9-trihydroxy-9,10-seconandrost-1,3,5(10)-triene-17-one; 3-HB, 3-hydroxybiphenyl; TC-FDM, two-component flavin-dependent monooxygenase; pHPAH, p-hydroxyphenyl acetate hydroxylase from A. baumanii; FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide; HPLC, high-performance liquid chromatography; GC-MS, gas chromatography/mass spectrometry; r.m.s.d., root mean square deviation; BSTFA, bis(trimethylsilyl)trifluoroacetamide; TMCS, trimethylchlorosilane.
cleavage and C-C bond hydrolysis by HsaC (5, 6) and HsaD (18) , respectively. In Mtb and RHA1, the hsaACDB genes occur in a single operon, and their respective products share 74 -82% amino acid sequence identity. In transposon mutagenesis studies, hsaA (3570c) was identified as one of 126 genes necessary for survival of Mtb in macrophages under conditions that model the immune response (4) .
Flavin-dependent monooxygenases (FDMs) constitute an important class of enzymes that utilize a reduced flavin to activate O 2 and hydroxylate a variety of organic substrates. Two broad classes are recognized based on whether the flavin is reduced and used to hydroxylate the substrate at a single active site (19) or whether flavin reduction and organic substrate hydroxylation occur at different sites, in two separate polypeptides. In the latter, referred to as two-component (TC-) FDMs, a reductase utilizes NADH to reduce the flavin, which is then transferred to the oxygenase (20) . The oxygenase generally has a preference for FADH 2 or FMNH 2 . Examples for the former include 4-hydroxyphenyl acetate 3-monooxygenase (HpaB) of Escherichia coli (21) and 2,4,5-trichlorophenol monooxygenase from Burkholderia cepacia (22) . FMN-dependent systems are involved in the synthesis of antibiotics such as actinorhodin in Streptomyces coelicolor (23) , the bacterial degradation of polyaminocarboxylates such as nitrilotriacetic acid (24) , and the desulfurization of fossil fuels by rhodococci (25) . pHPAH (EC 1.14.13.3), a well characterized FMN-utilizing enzyme from Acinetobacter baumanii, catalyzes the hydroxylation of p-hydroxyphenyl acetate (HPA) to 3,4-dihydroxyphenyl acetate (PDB entry 2JBT) (26) . The reductase component, C 1 , requires HPA for effective flavin reduction (27) , and the oxygenase component, C 2 , binds FMNH 2 prior to HPA (28) . HsaAB has been predicted to be a TC-FDM based on the ϳ32% amino acid sequence identity that it shares with C 2 and C 1 of pHPAH.
Herein we describe the characterization of HsaAB of Mtb. A ⌬hsaA mutant of RHA1 was used to investigate the enzyme's role in cholesterol catabolism and to generate substrates. To substantiate the role of the Mtb enzyme, each component was heterologously produced, purified, and used to reconstitute the enzyme's activity in vitro. The enzyme's specificity for a number of steroid metabolites was investigated. Finally, the crystal structure of HsaA was determined and compared with those of related oxygenases. The results are discussed with respect to TC-FDMs and the bacterial catabolism of steroids. Bacterial Strains and Culture Conditions-Escherichia coli strains were grown in Luria-Bertani (LB) medium at 37°C, 200 rpm. E. coli DH5␣ was used to propagate DNA. To produce HsaB, E. coli GJ1158 (29) containing pT7HB was grown at 30°C in low salt LB medium supplemented with 100 g ml Ϫ1 ampicillin. Expression of hsaB was induced when the culture attained an A 600 of 0.6 by adding NaCl to a final concentration of 0.3 M. Cells were further incubated for 16 h, harvested by centrifugation, washed twice with 20 mM sodium phosphate (pH 8.0) containing 10% glycerol, then frozen at Ϫ80°C until use. For metabolite analyses, R. jostii RHA1 ⌬hsaA mutant, RHA017 (30) , was grown in W minimal medium (31) supplemented with 0.5 mM cholesterol as described previously (6) . To produce HsaA, RHA017 containing pTipHA was grown at 30°C in LB supplemented with 25 g/ml chloramphenicol. Expression of hsaA was induced when the culture attained an A 600 of 0.8 by adding thiostrepton to a final concentration of 50 M. Cells were further incubated for 21 h prior to harvesting and freezing as described above.
MATERIALS AND METHODS
Heterologous Expression of HsaAB-DNA was propagated, digested, ligated, and transformed using standard protocols (32) . Plasmids were electroporated into RHA017 (30) and E. coli using a MicroPulser from Bio-Rad (Hercules, CA) with Bio-Rad 0.1-cm GenePulser Cuvettes. The hsaA (Rv3570c) and hsaB (Rv3567c) genes were amplified from Mtb H37Rv A, cholesterol is transformed to 3-hydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione (3-HSA) via previous enzymatic steps. HsaAB is proposed to catalyze the ortho hydroxylation of a phenol, 3-HSA, to a catechol, 3,4-dihydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione (3,4-DHSA). The latter is subsequently cleaved by HsaC to 4,5-9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oic acid (4,9-DSHA). B, other phenols that were used in this study: a, 3,17-DHSA; b, 3,9-DHSA; and c, 3-hydroxybiphenyl (3-HB). These are transformed by HsaAB to 3,4,17-THSA, 3,4,9-DHSA, and 2,3-dihydroxybiphenyl, respectively.
genomic DNA by PCR using the Expand High Fidelity and the following three-phase thermo-cycler program: 95°C for 5 min; 25 cycles of 95°C for 30 s, 57°C for 30 s, and 72°C for 1.5 min; and a final phase at 72°C for 7 min. The hsaA gene was amplified using a forward primer (GCAATAGCATATG-CATCACCATCACCATCACATCGAAGGTAGGACGTCC-ATTCAACACGTGATG), which introduced an NdeI site, six codons for histidine, and a Factor Xa recognition site, and a reverse primer (GCCAAGCTTGGTAGCTGTCATTTCG-CCTAGACC), which introduced a HindIII site. The amplicon was first cloned into pET41bϩ (Novogen, Oakville, Ontario) as an NdeI/HindIII fragment, its nucleotide sequence was verified, and then subcloned in pTipQC2 (33) using the same restriction sites, yielding pTipHA. The hsaB gene was amplified using oligonucleotides (CTAGCTAGCGC-TCAGATCGATCCACGCACG and GCCAAGCTTCGTCT-GCTCGCGCCACTAG) that introduced NheI and HindIII sites flanking the gene. The amplicon was cloned in pT7HP20 (34) as an NheI/HindIII fragment to yield pT7HB, from which HsaB is produced as an N-terminally His-tagged protein, HtHsaB. The nucleotide sequences of cloned amplicons were confirmed by the Nucleic Acid Protein Service at University of British Columbia.
Metabolite Analysis-Production of metabolites in culture supernatant was monitored using GC-MS as described below. Samples were analyzed directly or after BSTFAϩTMCS-(99:1) derivatization. When the metabolite concentration was judged to be maximal, the culture supernatant was collected by centrifugation and then extracted twice with one volume of ethyl acetate. The ethyl acetate fractions were pooled, dried with anhydrous magnesium sulfate, and evaporated to dryness with a rotary evaporator. Metabolites were purified by column chromatography (SiO 2 , n-hexane/ethyl acetate ϭ 2:3) and evaporated to dryness. To identify reaction products, substrates were dissolved to 205 M in 220 l of 20 mM sodium phosphate, pH 7.0, containing 25.8 M HsaA, 3 M HsaB⅐FMN, and 1 mM NADH. This mixture was incubated at 25°C for 30 min then extracted with 400 l of ethyl acetate and either directly analyzed via GC-MS or first dried under N 2 and derivatized using BSTFAϩTMCS (99:1).
Protein Purification-To purify HsaA, the pellet of RHA017 cells containing pTipHA obtained from 4 liters of culture was resuspended in 40 ml of 20 mM HEPES (pH 7.5) containing 1 mM dithiothreitol at 4°C. The cells were disrupted using 30 g of 0.1-mm zirconia/silica beads in a bead beater (Biospec Products, Bartlesville, OK) for five cycles of 2-min beating and 10-min incubation on ice. The chamber of the bead beater was immersed in ice water throughout the whole procedure after which the cell suspension was kept under N 2 and centrifuged (40,000 ϫ g, 45 min, 4°C). HsaA was purified in a Labmaster Model 100 glove box (M. Braun, Inc., Peabody, MA) operated at Ͻ5 ppm O 2 . The supernatant was passed through a 0.45-m filter (Sartorius AG, Göttingen, Germany) and loaded onto nickel-nitrilotriacetic acid-agarose (Qiagen) column (1.8 cm ϫ 5 cm) equilibrated with 20 mM sodium phosphate, pH 8.0, containing 10% glycerol. The purification was performed using an imidazole step gradient according to the instructions of the manufacturer. HsaA was eluted using 20 mM sodium phosphate, pH 8.0, containing 175 mM imidazole. The protein was exchanged into 20 mM HEPES, pH 7.5, 2 mM dithiothreitol, and 10% glycerol via ultrafiltration, concentrated to ϳ20 mg/ml, and flash frozen as beads in liquid N 2 .
HsaB Was Purified Using Essentially the Same Protocol with the Following Modifications-E. coli cells containing pT7HB from 1 liter of culture were used as the starting material; cells were disrupted using an Emulsiflex-05 homogenizer (Avestin, Ottawa, Ontario, Canada) operated at 10,000 p.s.i.; the manipulations were performed aerobically. The yellow-colored protein was exchanged into 25 mM HEPES, pH 7.5, containing 5% glycerol, concentrated to ϳ20 mg/ml, and flash frozen in liquid N 2 .
Identification of HsaB-bound Flavin-HsaB (20 l, 86 M) was diluted to 500 l using 20 mM potassium phosphate, pH 7.0, prior to denaturation by heat. The mixture was incubated at 100°C for 3 min, rapidly cooled on ice, and centrifuged at 10,000 ϫ g for 30 min at 4°C. The supernatant was passed through a 0.2-m filter and analyzed via HPLC using the method of Faeder and Siegel (35). Solutions of riboflavin, FMN, and FAD were used as standards.
Reconstitution of HsaB-Flavin-free HsaB was produced anaerobically in the glove box by incubating a 500-l solution of 86 M HsaB and 10 mM NADH in 20 mM HEPES, pH 7.6, for 5 min, then immediately passing the sample over a 0.5-ϫ 5-cm column of Biogel P6 (Bio-Rad) equilibrated with 20 mM HEPES, pH 7.6. HsaB was reconstituted by aerobically incubating the apoenzyme with 2 mM flavin for 1 h. Excess flavin was removed via ultrafiltration.
Analytical Methods-TLC was performed using silica gel 60 F 254 (Merck). Compounds were detected at 254 nm after first spraying plates with 50% sulfuric acid in ethanol and heating them for 5 min at 110°C. Preparative column chromatography was carried out on silica gel 60 (mesh size 40 -63 m). NMR spectra were recorded using a Varian Unity 500-MHz and an Inova 600-MHz (Varian Inc., Mississauga, Ontario, Canada) spectrometer. Chemical shifts (␦) are reported in ppm relative to CHCl 3 ( 1 H: ␦ ϭ 7.24) and CDCl 3 ( 13 C: ␦ ϭ 77.0) as internal standards. GC-MS was carried out using an HP 6890 series GC system fitted with an HP 5973 mass-selective detector and a 30-m ϫ 250-m HP-5MS Agilent column. The operating conditions were: T GC (injector), 280°C; T MS (ion source), 230°C; oven time program (T 0 min ), 104°C; T 2 min , 104°C; T 14.4 min , 290°C (heating rate 15°C⅐min Ϫ1 ); and T 29.4 min , 290°C. HPLC analysis were performed using a Waters 2695 Separations HPLC module equipped with a Waters 2996 photodiode array detector and a 250 ϫ 4.60 mm C18 Prodigy 10 ODS-Prep column (Phenominex, Torrance, CA). SDS-PAGE was performed using a Bio-Rad MiniPROTEAN III apparatus with a 10% or 12% resolving gel. Gels were stained with Coomassie Blue using standard protocols. Protein concentrations were determined using the Micro BCA TM protein assay kit (Pierce) and the Bradford method (36) using bovine serum albumin as a standard.
Enzyme Activity-HsaAB activity was measured spectrophotometrically by following the hydroxylation of 3-HB in a coupled assay with BphC (37) at 25 Ϯ 0.5°C. Reactions were performed in 125 l of 20 mM potassium phosphate, pH 7.0, containing 1.6 mM 3-HB, 2.8 M BphC, 4 M HsaB⅐FMN, and 10.2 M HsaA. Components were incubated for 30 s, then the reaction was initiated by adding NADH to a final concentration of 600 M and was monitored at 434 nm, the absorbance maximum of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid (⑀ 434 ϭ 16.9 mM Ϫ1 cm Ϫ1 ). Stock solutions were prepared fresh daily. Absorbance was monitored using a Varian Cary 5000 spectrophotometer controlled by WinUV software. One unit of activity was defined as the amount of enzyme required to consume 1 mol of substrate per minute.
Steady-state kinetic parameters were evaluated using standard conditions except that for 3-HSA and 3,17-DHSA, 11.7 M HsaC was used instead of BphC. Substrate concentrations were varied over the following ranges: 90 -1600 M for 3-HB and 30 -1000 M for each of 3-HSA and 3,17-DHSA. The molar absorptivities of 4,9-DSHA and 4,9-DSDHA were 2.41 and 2.40 mM Ϫ1 cm
Ϫ1
, respectively, at 392 nm (pH 7.0). In these studies, HsaA was thawed and stored under N 2 in a sealed vial on ice. Aliquots were withdrawn using a gas-tight syringe. Kinetic parameters were evaluated by fitting the Michaelis-Menten equation to the data using the least-squares fitting and dynamic weighting options of LEONORA (38) .
The steady-state kinetic parameters for O 2 were determined using a Clarke-type electrode (Hansatech Instruments Ltd., Norfolk, England) interfaced to a computer equipped with the Oxygraph Plus software. The reaction buffer was equilibrated for 20 min by vigorous bubbling with mixtures of N 2 and O 2 prior to the reaction, and the reaction cuvette was continually flushed with the same gas mixture during the reaction. The assay was performed in 500 l containing 660 M 3-HSA, 0.2 M HsaB, and 10.2 M HsaA. The reaction was initiated by adding NADH to 500 M. After 60 s, 603 units of catalase was added to the reaction mixture. The rate of O 2 consumption prior to catalase addition (v O2 ) was taken to represent the rate of substrate hydroxylation (v ROH ) plus the rate of adventitious production of H 2 O 2 . The rate after catalase addition (v ϩC ) was taken to represent v ROH plus 50% of the rate of adventitious production of H 2 O 2 . Thus, v ROH was calculated from 2v ϩC Ϫ v O2 .
Static Light Scattering-Purified HsaA in solution was analyzed by the triple-angle light-scattering detector (Wyatt MiniDAWN Tristar) connected on-line to a size-exclusion chromatography column (Amersham Biosciences, Superdex 200 HR 10/30). The gel-filtration buffer contained 20 mM HEPES, pH 7.5, 150 mM NaCl, and 10% glycerol (v/v). The molecular weights of HsaA fractions were calculated using the ASTRA software (Wyatt Technology).
Crystallization-HsaA was crystallized under two conditions. In the first, crystals of protein purified aerobically from E. coli were grown aerobically at 18°C using the hanging drop, vapor-diffusion method using aerobically purified HsaA. 1 l of 20 -25 mg/ml protein was mixed with 1 l of crystallization solution (2 M sodium formate, 0.1 M sodium acetate, pH 4.6). Single flattened rod-like crystals appeared in ϳ10 days and grew to their full size (250 m ϫ 80 m ϫ 50 m) in ϳ2 weeks. Prior to data collection HsaA crystals were briefly transferred to a series of solutions containing 80% of the equilibrated reservoir solution supplemented with increasing amounts of ethylene glycol (5-20%) and flash frozen in liquid N 2 . In the second, crystals of protein purified anaerobically from RHA1 were grown anaerobically at 23°C in the above-described glove box using the sitting drop, vapor-diffusion method and anaerobically purified HsaA. 1 l of 11 mg/ml protein was mixed with 1 l of crystallization solution (0.1 M Tris-HCl, pH 7.0, 20% (w/v) polyethylene glycol-2000 MME). Thin plates were obtained within 3 days. Crystals were harvested directly from the mother liquor and were flash frozen in liquid nitrogen in the anaerobic chamber prior to data collection.
X-ray Data Collection and Structure Determination-X-ray data were collected under cryogenic conditions using a rotating anode x-ray generator (CuK ␣ radiation ϭ 1.542 Å) and synchrotron radiation at the Canadian Light Source (beamline CMCF1, ϭ 1.000 Å). Data were processed using XDS (39) or HKL2000 (40) . The initial model and phase information were obtained from aerobically grown crystals by molecular replacement using the structure of substrate-free pHPAH (PDB entry 2JBS) and the program EPMR (41) . Crystals grew in the space group I222 with two copies of HsaA in the crystallographic asymmetric unit. Model building and structure refinement were performed using CNS (42) and REFMAC (43) . Anaerobically, crystals grew in space group P2 1 with four molecules of HsaA in the asymmetric unit. The structure was solved using the structure of aerobically grown HsaA as the starting model and MOLREP (43) , and was refined as described above.
Data collection and refinement are summarized in Table 3 . Electron density maps were calculated using the CCP4 package (44) . Structural figures were made with the program PyMOL (45) . The coordinates for the two Mtb HsaA conformations were deposited in the Brookhaven Protein Data bank with accession codes 3AFE and 3AFF.
Molecular Docking Simulation and Modeling-3-HSA was designed using PRODRG (46), energy was minimized using the Dreiding force field (47) , and PM6 semi-empirical charges were calculated using MOPAC2007 (48) . After removing water molecules from the HsaA O and HsaA C models, docking simulations were initially performed using PATCHDOCK (49) . Significant clusters that placed the ligand molecule in the correct orientation with respect to the cofactor were picked and run through Autodock version 4.0 (50) with active site residues held rigid and the initial torsion angles of 3-HSA randomly set.
Solutions of the best free energy were minimized with strong restraints (Force 200) until gradient norm convergence to 1.0, over the entire system (heavy atoms only) with the exception of a sphere of 8 Å around the active site. Residues within this sphere were unrestrained to allow for minor side-chain re-orientations. The cofactor was kept rigid during all calculations and was positioned based on the closely similar binding site of pHPAH. Structural figures and graphics were rendered using PyMOL (45) .
RESULTS
Phenotype of the hsaA Deletion Mutant-Bioinformatic analyses indicate that HsaAB of the actinomycete cholesterol catabolic pathway is a TC-FDM that transforms 3-HSA to 3,4-DHSA (5). To test this prediction, we investigated the phenotype of RHA017, an hsaA deletion mutant of RHA1 (30) .
Consistent with the enzyme playing a central role in cholesterol catabolism, the deletion strain did not grow on cholesterol but grew normally on pyruvate (data not shown). When pyruvategrown cells of RHA017 were incubated in the presence of cholesterol, four major metabolites accumulated in the medium ( Fig. 2A) . Purification of the three major ones afforded 3-HSA and two keto-reduced versions thereof: 3,9-DHSA and 3,17-DHSA. These were characterized using GC-MS and 1 H-, 13 C-, (H,H)-COSY-, HSQC-, and HMBC-NMR as summarized in the supplemental materials. The fourth metabolite was identified as 3,9,17-THSA using GC-MS.
Purification of HsaAB-HsaA produced in E. coli and purified aerobically had a very low specific activity. Production of the protein in RHA017 using pTipHA increased the specific activity by an order of magnitude; anaerobic purification further increased this 2-fold. This approach typically yielded 25 mg of purified HsaA per liter of culture with an apparent purity of Ͼ95% according to SDS-PAGE analysis and a specific activity of 0.12 unit/mg using 3-HB in the standard assay. Proteolytic removal of the N-terminal His tag did not significantly affect the specific activity. Accordingly, His-tagged HsaA was used in this study.
Purification of HsaB from E. coli (pT7HB) yielded 25 mg of protein per liter of culture. The purified preparation was Ͼ95% HsaB as judged from SDS-PAGE and had absorption maxima at 268, 370, and 448 nm consistent with the presence of oxidized flavin (supplemental Fig. 1A) . HPLC analyses of the acid-extracted flavin revealed two species with retention times and spectra corresponding to FMN and FAD, respectively (supplemental Fig. 1B) . In subsequent experiments, HsaB was reconstituted with either FMN or FAD as solely bound cofactor.
HsaAB Catalyzes o-Hydroxylation-As noted above, RHA017 cultures incubated with cholesterol accumulated 3-HSA, 3,9-DHSA, 3,17-DHSA, and 3,9,17-THSA. When the culture supernatant was incubated for 30 min at room temperature with 9 M HsaA, 4 M HsaB⅐FMN, and 600 M NADH, 3-HSA and 3,17-DHSA were removed from the mixture and two new compounds were detected by GC-MS (Fig. 2B) . Mass spectrometry and NMR spectroscopy identified these compounds as 3,4-DHSA and 3,4,17-THSA (supplemental materials). Under similar conditions, HsaAB transformed 3-HB to 2,3-dihydroxybiphenyl, as confirmed by GC-MS (supplemental materials). These results demonstrate that HsaAB of Mtb is able to catalyze the o-hydroxylation of a range of p-substituted phenols to generate the corresponding catechols.
Steady-state Kinetic Analyses-To evaluate the specificity of HsaAB for different substrates, a coupled spectrophotometric assay was developed in which the catechol produced by the HsaAB reaction was cleaved by an extradiol dioxygenase (HsaC or BphC) to yield the yellow-colored meta-cleavage product. Dioxygenase concentrations were adjusted so as not to be ratelimiting. The concentration of HsaA was 2.5-fold higher than that of HsaB to maximize coupling between these components (see below). In all studies, the inferred initial rates of hydroxylation displayed Michaelis-Menten kinetics (Fig. 3) . The evaluated kinetic parameters are considered to be apparent as they are dependent on the ratio of HsaA and HsaB as well as the concentration of O 2 .
The coupled assay was performed with 3-HSA to evaluate the ability of HsaAB to utilize different flavins. In the presence of 4 M exogenously added FMN or FAD, no increase in enzyme activity was observed. By contrast, 4 M riboflavin inhibited the activity by ϳ50%. To further evaluate the ability of HsaAB to utilize FMN and FAD, the reductase was reconstituted with each flavin as sole cofactor. As summarized in Table 1 , the apparent specificity of HsaAB for 3-HSA was remarkably similar for assays containing HsaB⅐FMN and HsaB⅐FAD. However, the apparent k cat and K m values were ϳ3-fold greater in the presence of HsaB⅐FMN. All subsequent kinetic studies were performed using HsaB⅐FMN and without supplementary flavin.
The coupled assay was then used to evaluate the specificity of HsaAB for various p-substituted phenols. Of the purified steroid metabolites, the mycobacterial enzyme had slightly higher apparent specificity (k cat /K m ) for 3-HSA versus 3,17-DHSA (Table 1) . By contrast, the apparent specificity for 3-HB was an order of magnitude lower. Nevertheless, the apparent k cat values for these p-substituted phenols were within a factor of two. Remarkably, the activity of 3,9-DHSA was too low to evaluate kinetic parameters. However, in an assay using 205 M 3,9-DHSA and 25.8 M HsaA, GC-MS analyses demonstrated that the phenol was transformed to 3,4,9-THSA and that this reaction occurred with one-third the efficiency of the 3-HB transformation.
An oxygraph assay was developed to investigate the reactivity of HsaAB with O 2 . In developing this assay, it was noted that O 2 was consumed in the absence of HsaA. This HsaB-dependent O 2 consumption resulted in quantitative H 2 O 2 production as indicated by the addition of catalase (results not shown). To minimize uncoupled O 2 consumption, assays were performed using 10-fold less HsaB than in the spectrophotometric assay. The remaining H 2 O 2 production was corrected for by measuring the rate of O 2 consumption before (v O2 ) and after (v ϩC ) the addition of catalase. The calculated rate of O 2 consumption due to hydroxylation, v ROH , was within 5% of that determined using the spectrophotometric assay and the same concentration of HsaB. Using the oxygraph assay and saturating amounts of 3-HSA, the apparent K mO2 was 100 Ϯ 10 M (Table 2) .
Overall Structure-The refined structure of HsaA purified aerobically from E. coli contains two peptide chains (residues 
b R work ϭ ⌺ʈF obs ͉ Ϫ ͉F calc ʈ/⌺͉F obs ͉. R free is the R work value for 5% of the reflections excluded from the refinement. Data for the highest resolution shell are given in parentheses.
4 -391), two formate ions, and 669 water molecules in the asymmetric unit (Table 2 and Fig. 4 ). Due to the lack of visible electron density, the model does not include three portions of the molecule: the N terminus (the His tag and residues 1-3), the C terminus (residues 391-394), and residues 261-282. As presented below, the F o Ϫ F c difference map revealed a ring-shaped 6-positive peak in the substrate-binding site of the enzyme. This density was not assigned but likely represents an E. coli metabolite that co-purified with the enzyme. In comparison, the refined structure of anaerobically prepared HsaA purified from RHA1 contains four peptide chains (residues 3-394) and 472 water molecules. N-terminal residues 1-3 and residues 271-272 were not visible in any of the four molecules of the asymmetric unit. ) and a bundle of ␣-helices (Fig. 4A) (Fig. 4B) . Static light scattering analysis indicated that HsaA prepared aerobically from the E. coli host exists as a mixture of dimers and octamers in solution while HsaA prepared anaerobically from the rhodococcal host exists as a tetramer (supplemental Fig. 2) .
Conformational States of the C-terminal Flap-Comparison of the tetrameric HsaA
O and octameric HsaA C revealed different contacts between HsaA protomers in the crystal lattice, as reflected by the difference in buried surface area described above. In addition, two regions of the molecule displayed conformational differences that likely further contribute to the difference in crystal packing: an apical hairpin turn (Gly ). In HsaA O (P2 1 ), the C-terminal helix bundles (Fig. 4A) are clustered toward the center of the tetramer (Fig. 4A) , forming a coiled-coiled complex, with the ␤-barrel projecting outward in the tetrahedral arrangement (Fig. 4B) . At the center of the tetramer, a helixturn-helix motif (Glu 317 -Gly 365 ) composed of residues immediately preceding those of the C-terminal flap, stacks and aligns anti-parallel to the equivalent motif in the adjacent protomer. Moreover, the same cluster of residues from the two protomers comprises the major direct noncovalent interactions at the interface: Phe 341 By contrast, the intersubunit interactions in the HsaA C octamer are more intricate (Fig. 4C) , with each protomer interacting with three others. At one end, each protomer interacts with its neighbor through their respective helix-turn-helix motifs in much the same way as in HsaA O . At the other end, contact with a third protomer involves hydrophobic interactions between C-terminal flaps at the entrance of the active site with residues of adjacent protomers, Ile 376 , Tyr 374 , Phe 377 , and Phe 382 , involved. In comparison to its conformation in HsaA O , the flap in HsaA C differs by a 25°rigid body rotation around Arg 366 (Fig.  5C ) enabling the described intersubunit association and effectively occluding the entrance to the substrate-binding pocket of HsaA. Finally, our structures suggest that the interface between the C-terminal flaps is spatially positioned to potentially interact with the apical hairpin turn (disordered in our HsaA C structures) of an adjacent protomer (Fig. 4D) .
The two conformers also differ in the degree of flexibility of their C-terminal segments, with the B-factors increasing toward the C-terminal flap residues, reaching an average value of 50.6 Å 2 for the backbone C␣s of Pro 388 -Val
394
. This value is ϳ2-fold higher than that of the rest of the protein. By contrast, the B-factors of the C-terminal flap in HsaA C are comparable to those of the surrounding residues (ϳ27.6 Å 2 ) and are similar throughout the flap.
We considered whether oxidation of a Cys residue might influence the conformation of the C-terminal flap of HsaA. Inspection of the two structures revealed that Cys 63 , Cys 79 , and Cys 145 all have low solvent accessibilities and are remote (Ͼ20 Å) from the C-terminal flap. Inspection of the electron density revealed no evidence for oxidation. Thus, 2F o Ϫ F c and F o Ϫ F c maps revealed no additional electron density around the Cys thiols in the structure of the aerobically prepared enzyme. Moreover, water molecules are ordered around the cysteines in a similar fashion in both HsaA C and HsaA O . Overall, our data indicate that oxidation of a Cys residue does not contribute to the different conformation of the C-terminal flap.
The Flavin Binding (F-)Subsite-The structures of HsaA contain a deep cavity that presumably sequesters the substrates: reduced flavin, O 2 , and 3-HSA. This cavity is located at the interface between the C-terminal helix bundle and the ␤-barrel. Superposition of the structure of the pHPAH⅐flavin⅐pHPA complex facilitates the description of the substrate-binding pocket of HsaA (Fig. 6A) . Notably, the pocket comprises two adjacent subsites: the H-subsite binds the phenol, and the slightly more solvent-accessible F-subsite binds the reduced flavin. The F-subsite of HsaA O is remarkably similar to that of pHPAH with all first shell residues being conserved (i.e. . Finally, the entrance to the F-subsite is lined with charged residues and is partially occluded by an adjacent protomer in the tetramer, as observed in pHPAH. However, although residues contacting the isoalloxazine moiety are largely conserved, side chains that stabilize the phosphate group, located on a C-terminal helix, are not (i.e. Asn 371 ). The F-subsite in the HsaA C crystal form is very similar, but differs in two respects. First, the entrance to the subsite is occluded by the C-terminal flap. Second, the flavin binding site is partially occupied by Trp 139 and His 368 . The 3-HSA Binding (H-)subsite-In contrast to the F-subsite, the H-subsite is buried in the core of the protein and is predominantly lined with hydrophobic residues: Trp 94 , Pro 238 , Ile 241 , Tyr 210 , His 237 , and Trp 233 . These residues are conserved in HsaA of R. jostii RHA1 but not in pHPAH. The size of the HsaA H-subsite versus that of pHPAH is consistent with the former accommodating a larger phenolic substrate.
To investigate the structural basis of binding of the phenolic substrate, we modeled 3-HSA into the H-subsite of HsaA O and HsaA C using molecular docking and energy minimization methods. The high structural similarity of the F-subsites of HsaA O , HsaA C , and pHPAH⅐flavin⅐pHPA allowed for positioning of flavin in the binding site. In both forms of HsaA, the His 368 and Trp 141 side chains were the only ones of the F-subsite that required minor reorientation to accommodate the fla- vin. The latter molecule was kept rigid during docking and energy minimization calculations. Positive clustering of docked solutions was readily observed using either HsaA O or HsaA C , with the best positional conformation placing the substrate in close proximity to the flavin molecule. A solution where the C4 atom of 3-HSA is within 4.2 Å to the C4a atom of the cofactor was chosen as the strongest candidate for further energy minimization. In docking 3-HSA, a number of aromatic side chains interacting with the bicycloalkanone moiety underwent rearrangement during the docking and energy minimization process.
In the modeled HsaA C ⅐flavin⅐3-HSA complex, the phenol ring of 3-HSA is orientated toward the flavin and the bicycloalkanone moiety toward the entrance to the active site, stacking against Pro 373 (Fig. 6B) . The modeled complex shares at least three important features with the pHPAH⅐flavin⅐pHPA complex. First, the phenol ring is orthogonal to the flavin. Second, conserved Ser 118 in HsaA appears to interact with the phenolic ring in such a way as to favor the deprotonated form of the hydroxyl group located 2.4 Å away. Third, there is a cavity between flavin C4a and phenol C4 that can accommodate O 2 (Fig. 6C ). More specifically, the distance between flavin C4a and phenol C4 is 4.9 Å, compatible with the formation of a C4a-hydroperoxyflavin intermediate on the reface of the isoalloxazine ring (Fig. 6C) . In the modeled complex, the probable O 2 -binding cavity is slightly larger than in the pHPAH⅐flavin⅐pHPA complex (29 Å 3 versus 18 Å 3 ) due to the presence of less bulky residues (e.g. Phe 270 in pHPAH is Ile 241 in HsaA). Finally, the unassigned electron density in HsaA C occupies a space corresponding to a portion of the iso-alloxazine ring of the flavin and the phenol ring of the 3-HSA (Fig. 6D) .
Two notable features of the modeled HsaA C ⅐3-HSA interactions involve C9 and C17 of the substrate (Fig. 6, B and E 
DISCUSSION
The current study establishes that the role of mycobacterial and rhodococcal HsaAB is to transform 3-HSA to 3,4-DHSA in the catabolism of cholesterol. When incubated in the presence of cholesterol, a ⌬hsaA mutant of RHA1 accumulated the enzyme's predicted substrate, 3-HSA, together with related metabolites in which the keto groups on the bicycloalkanone moiety are reduced. Consistent with its predicted role, reconstituted HsaAB from Mtb had the highest specificity for 3-HSA. Moreover, the crystal structure of HsaA revealed a fold that is typical of TC-FDM oxygenases and a substrate-binding pocket that is well adapted to the steroid metabolite. The function of HsaAB is consistent with transposon mutagenesis studies indicating that hsaA (3570c) is necessary for survival of Mtb in macrophages, but hsaB (3567c) is not (4), because it is likely that flavin-reducing function of HsaB could be performed by another enzyme.
The metabolite analyses of the ⌬hsaA mutant suggest that at least in RHA1, side-chain degradation largely precedes ring degradation. More specifically, the identified metabolites represented either the end (C17 ketone) or penultimate (C17 hydroxy) product of side-chain degradation. This is consistent with the recent finding that cytochrome P450 125 initiates cholesterol degradation in this strain by hydroxylating a terminal carbon (11) . Nevertheless, the ⌬hsaC mutant of RHA1 accumulated three major catecholic metabolites possessing the ketone, hydroxyl, as well a propionate group at C17, 7 consistent with some simultaneous degradation of the side chain and rings. The different metabolites in the two mutants may reflect the relative specificities of the side chain-degrading enzymes for the phenolic versus catecholic steroid metabolites. Finally, the significance of the 9-hydroxy metabolites, 3,9-DHSA and 3,9,17-THSA, is unclear. Their relative lack of reactivity with HsaAB suggests that they may have arisen adventitiously in the mutant. The current studies do not rule out the possibility that the physiological substrate of HsaAB is 3-HSA with a partially degraded side chain.
Although the activity of HsaAB is lesser than that of other characterized TC-FDMs, it is consistent with that of other cholesterol catabolic enzymes of Mtb. For example, the apparent specificity (k cat /K m ) of a bacterial EDTA monooxygenase for MgEDTA 2Ϫ is 430-fold greater than that of HsaAB (51). Simi- larly, the apparent specificity of alkanesulfonate monooxygenase for alkanesulfonates was up to 112-fold greater (25) . Nevertheless, the relative activity of HsaAB is very similar to that of its flanking enzymes in the cholesterol catabolic pathway, KshA (17) ), respectively, would help minimize intracellular concentrations of the latter, which is toxic to Mtb (6) .
HsaA is similar to pHPAH oxygenase (52) in that both utilize FMNH 2 and FADH 2 with similar efficiencies and that exogenously added flavin does not increase the rate of product formation by either enzyme. Nevertheless, the structure of HsaA suggests that the F-subsite recognizes the isoalloxazine ring of FMNH 2 or FADH 2 and does not accommodate the entire FADH 2 molecule: the adenyl moiety of the latter would protrude into bulk solvent (supplemental Fig. 3 ). In nitroalkane oxidase from Fusarium oxysporum (PDB entry 2C0U), the protruding moiety mediates subunit interactions. Other bacterial TC-FDMs that transform aromatic compounds preferentially utilize one of the flavins: FMNH 2 in the case of pristinamycin II A synthase (53) and FADH 2 in the case of chlorophenol-4-hydroxylase (54), pyrrole-2-carboxylate monooxygenase (55) , and p-nitrophenol hydroxylase (56) .
Although the closed conformation of the C-terminal flap correlates with the presence of an active site ligand in HsaA, it is unclear how the expression host (E. coli versus Rhodococcus) and the exposure of the enzyme to O 2 during purification contribute to the presence of the ligand. Moreover, the functional significance of the different conformations in HsaA O and HsaA C and the octameric state of the latter remains unclear. In the enzyme's closed conformation, the C-terminal flap likely prevents the entry of the reduced flavin, the first substrate to bind in the related pHPAH (28) . Nevertheless, modeling studies indicate that the closed conformation better accounts for the low specificity of HsaA for 3,9-DHSA, as described below. It is possible that, in solution, a change in conformation in the C-terminal flap favored by flavin binding might help direct the subsequent entry of the organic substrate. The flap is present in all TC-FDM oxygenases structurally characterized to date, including pHPAH, HpaB (PDB entry 2YYG), HsaA from RHA1 (PDB entry 2RFQ), as well as two related enzymes: pig medium chain acyl-CoA dehydrogenase (PDB entry 2JIF) and nitroalkane oxidase from F. oxysporum (PDB entry 2C0U). In all cases, the enzymes were tetrameric and the flap was in the same conformation as in the HsaA O structure. However, alternate conformations of the flap may not have been observed in four of these cases, because the enzymes were crystallized in the presence of reduced flavin and the corresponding organic substrate. Structural flexibility in pHPAH (48) and HpaB (56) is suggested by elevated B-factors of the C-terminal flap residues, as observed in HsaA O . Finally, it is also possible that octameric HsaA C represents a more stable form of the enzyme present in metabolically quiescent bacterial cells. Regardless of its functional significance, the orientation of the flap in the aerobically purified HsaA from E. coli together with the presence of a ligand in the F-subsite of this preparation correlates with its decreased catalytic activity. The structural data provide at least two intriguing insights into the substrate specificity of HsaA (Fig. 6, E and F) . First, the predicted proximity of the C9 ketone with Asp 372 (3.7 Å) may explain why 3,9-DHSA is a poor substrate inasmuch as the 9-OH substitution may disrupt the hydrogen bond between Asp 372 and His 368 . This may ultimately perturb the catalytic function of the latter. Second, the channel that extends from the C17 ketone suggests that the H-subsite can accommodate substrates with partially degraded side chains. This raises the possibility that the physiological substrates of the steroid ring-degrading enzymes have not yet been identified, consistent with the relatively low specificity constants of these enzymes for side chain degraded metabolites.
It remains unclear whether cholesterol catabolism is essential to the pathogenesis of Mtb (6 -8). Nevertheless, transposon mutagenesis studies indicate that HsaAB activity is critical for survival in macrophages (4) . Further studies of HsaAB should help establish the role of cholesterol catabolism in the pathogenesis of Mtb as well as the catalytic mechanism of TC-FDMs. Indeed, characterization of the ligand bound to HsaA C may be useful in both of these respects. shown.
